NCT01625754 · COMPLETED
The Heart-Mind Connection: Evaluating the Association Between Ceramides and Cognitive Decline in Coronary Artery Disease
This study follows 129 people with coronary artery disease in a cardiac rehab program. Researchers will check memory and blood levels of ceramides, fat byproducts that may harm brain cells, at the start, 3 months and 6 months. The goal is to see whether the two are linked. It is observational, so it tests no treatment and has no formal phase.
Eligibility criteria
Inclusion Criteria: * 50-75 years of age * speak and understand English * evidence of CAD based on at least 1 of the following: * previous hospitalization for myocardial infarction * angiographic evidence of ≥ 50% blockage in ≥ 1 major coronary artery * a prior revascularization procedure * no recent (last 4 weeks) hospitalization for cardiac events such as acute myocardial infarction, unstable angina, congestive heart failure, ventricular arrhythmias, coronary revascularization, or Canadian Cardiovascular Society Class 4 angina Exclusion Criteria: * Type I diabetes * hypothyroidism, Parkinson's disease, any diagnosis of dementia including Alzheimer's disease, inflammatory disease (irritable bowel syndrome, Crohn's, arthritis, etc.), Huntington's chorea, brain tumour, other conditions that may affect cognitive performance such as history of epilepsy, subdural hematoma, traumatic brain injury, and clinical stroke, progressive supranuclear paralysis, Killip Class III or IV states, multiple sclerosis, severely disrupted liver/ kidney/ lung function * use of hypnotics, antipsychotics, antidepressants, and anticholinergic medication * premorbid psychiatric diagnosis of schizophrenia or bipolar disorder * significant cognitive impairment (MMSE ≤ 24) * diagnosis of any current Axis I disorder other than depression, phobias or nicotine abuse/dependence
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2024-01-31